<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D81BE73D-DD20-47CC-9D35-0EA321DA76D8"><gtr:id>D81BE73D-DD20-47CC-9D35-0EA321DA76D8</gtr:id><gtr:name>Cardiology Frankfurt-Sachsenhausen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/215C8CB9-38B2-495F-89F4-21D4414B80C6"><gtr:id>215C8CB9-38B2-495F-89F4-21D4414B80C6</gtr:id><gtr:name>University of California, Berkeley</gtr:name><gtr:address><gtr:line1>University of California, Berkeley</gtr:line1><gtr:line2>191 University Hall</gtr:line2><gtr:postCode>CA 94720</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A919B771-5C0F-4AD1-B747-03D25677DC3B"><gtr:id>A919B771-5C0F-4AD1-B747-03D25677DC3B</gtr:id><gtr:name>University of Texas Southwestern Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6711BFCB-ACD5-4149-9C97-283269DF2778"><gtr:id>6711BFCB-ACD5-4149-9C97-283269DF2778</gtr:id><gtr:name>Mayo Clinic</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/916B2286-CD84-4805-9E62-358639644585"><gtr:id>916B2286-CD84-4805-9E62-358639644585</gtr:id><gtr:name>Intermountain Medical Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FAE32A25-51D3-49EF-998F-281B3A47C212"><gtr:id>FAE32A25-51D3-49EF-998F-281B3A47C212</gtr:id><gtr:name>Helmholtz Association of German Research Centres</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CF449342-AF1A-4D3F-B833-8F6DB8687F7D"><gtr:id>CF449342-AF1A-4D3F-B833-8F6DB8687F7D</gtr:id><gtr:name>Uppsala University Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/62C544E8-A6D5-4B0C-9773-7A30B21F968D"><gtr:id>62C544E8-A6D5-4B0C-9773-7A30B21F968D</gtr:id><gtr:name>University of Padua</gtr:name><gtr:address><gtr:line1>Universita di Padova</gtr:line1><gtr:line4>Padova</gtr:line4><gtr:postCode>35129</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/71B6CE06-9A78-427F-8FF2-50FCA9069AD8"><gtr:id>71B6CE06-9A78-427F-8FF2-50FCA9069AD8</gtr:id><gtr:name>Central Hospital of Bolzano</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F"><gtr:id>FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F</gtr:id><gtr:name>Baylor College of Medicine</gtr:name><gtr:address><gtr:line1>Baylor College of Medicine</gtr:line1><gtr:line2>Texas Medical Center</gtr:line2><gtr:line4>Houston</gtr:line4><gtr:line5>Texas</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/007E0817-B05C-490A-B38A-2EDA79558DDD"><gtr:id>007E0817-B05C-490A-B38A-2EDA79558DDD</gtr:id><gtr:name>Boston University</gtr:name><gtr:address><gtr:line1>One Sherborn Street</gtr:line1><gtr:line2>Boston</gtr:line2><gtr:line3>Massachusetts</gtr:line3><gtr:line4>MA 02215</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B62A7F23-290D-4D84-B017-FBBDF6E49E3D"><gtr:id>B62A7F23-290D-4D84-B017-FBBDF6E49E3D</gtr:id><gtr:name>University of Vermont</gtr:name><gtr:address><gtr:line1>University of Vermont</gtr:line1><gtr:line4>Burlington</gtr:line4><gtr:line5>Vermont</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8D42AFBE-6916-4BC6-8D6B-7BA1516690D2"><gtr:id>8D42AFBE-6916-4BC6-8D6B-7BA1516690D2</gtr:id><gtr:name>Malmo University Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/92B1EEF6-3D49-49C5-A7A5-5290AD810F6B"><gtr:id>92B1EEF6-3D49-49C5-A7A5-5290AD810F6B</gtr:id><gtr:name>University Medical Center Freiburg</gtr:name><gtr:address><gtr:line1>Robert-Koch-Str. 1</gtr:line1><gtr:postCode>D-79106</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C754D612-4D8B-42CB-922C-07E7F5BE4B49"><gtr:id>C754D612-4D8B-42CB-922C-07E7F5BE4B49</gtr:id><gtr:name>Washington University in St. Louis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0DE3D2C5-5503-42B3-A8A5-7F3FD1EE8DE8"><gtr:id>0DE3D2C5-5503-42B3-A8A5-7F3FD1EE8DE8</gtr:id><gtr:name>Geisinger Medical Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B"><gtr:id>22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B</gtr:id><gtr:name>University of Ulm</gtr:name><gtr:address><gtr:line1>Albert Einstein Allee 5</gtr:line1><gtr:line4>Ulm</gtr:line4><gtr:postCode>89081</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E68BE577-6C17-48CE-B65C-24C477BB8AE9"><gtr:id>E68BE577-6C17-48CE-B65C-24C477BB8AE9</gtr:id><gtr:name>Yeshiva University</gtr:name><gtr:address><gtr:line1>500 West 185th Street</gtr:line1><gtr:postCode>10033</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB"><gtr:id>60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB</gtr:id><gtr:name>Brigham and Women's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AD1B5C1D-39E1-4A1F-A58F-D5F2DE64FE7F"><gtr:id>AD1B5C1D-39E1-4A1F-A58F-D5F2DE64FE7F</gtr:id><gtr:name>Innsbruck Medical University</gtr:name><gtr:address><gtr:line1>Christoph-Probst-Platz 1</gtr:line1><gtr:line2>Innrain 52</gtr:line2><gtr:postCode>A-6020</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8A621CD6-4DE9-4B35-992C-631871D7793E"><gtr:id>8A621CD6-4DE9-4B35-992C-631871D7793E</gtr:id><gtr:name>University of Rochester</gtr:name><gtr:address><gtr:line1>PO Box 270001</gtr:line1><gtr:line4>Rochester</gtr:line4><gtr:line5>New York</gtr:line5><gtr:postCode>NY 14627</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8C250FB6-4890-4BF9-9C23-69E6B2E02B95"><gtr:id>8C250FB6-4890-4BF9-9C23-69E6B2E02B95</gtr:id><gtr:name>Wake Forest University</gtr:name><gtr:address><gtr:line1>Wake Forest University</gtr:line1><gtr:line2>1834 Wakeforest Road</gtr:line2><gtr:line4>Winston Salem</gtr:line4><gtr:line5>North Carolina</gtr:line5><gtr:postCode>NC 27106</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/926FCE3B-DFAB-4FE7-9BF8-7372B5AA9514"><gtr:id>926FCE3B-DFAB-4FE7-9BF8-7372B5AA9514</gtr:id><gtr:name>German Cancer Research Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AFCF678A-5FC2-4D86-B376-12C1457C0F14"><gtr:id>AFCF678A-5FC2-4D86-B376-12C1457C0F14</gtr:id><gtr:name>Columbia University Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC"><gtr:id>AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC</gtr:id><gtr:name>Johannes Gutenberg University of Mainz</gtr:name><gtr:address><gtr:line1>University of Mainz</gtr:line1><gtr:line4>Mainz</gtr:line4><gtr:postCode>D-55099</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Institute of Public Health</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D81BE73D-DD20-47CC-9D35-0EA321DA76D8"><gtr:id>D81BE73D-DD20-47CC-9D35-0EA321DA76D8</gtr:id><gtr:name>Cardiology Frankfurt-Sachsenhausen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/215C8CB9-38B2-495F-89F4-21D4414B80C6"><gtr:id>215C8CB9-38B2-495F-89F4-21D4414B80C6</gtr:id><gtr:name>University of California, Berkeley</gtr:name><gtr:address><gtr:line1>University of California, Berkeley</gtr:line1><gtr:line2>191 University Hall</gtr:line2><gtr:postCode>CA 94720</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A919B771-5C0F-4AD1-B747-03D25677DC3B"><gtr:id>A919B771-5C0F-4AD1-B747-03D25677DC3B</gtr:id><gtr:name>University of Texas Southwestern Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6711BFCB-ACD5-4149-9C97-283269DF2778"><gtr:id>6711BFCB-ACD5-4149-9C97-283269DF2778</gtr:id><gtr:name>Mayo Clinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/916B2286-CD84-4805-9E62-358639644585"><gtr:id>916B2286-CD84-4805-9E62-358639644585</gtr:id><gtr:name>Intermountain Medical Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FAE32A25-51D3-49EF-998F-281B3A47C212"><gtr:id>FAE32A25-51D3-49EF-998F-281B3A47C212</gtr:id><gtr:name>Helmholtz Association of German Research Centres</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CF449342-AF1A-4D3F-B833-8F6DB8687F7D"><gtr:id>CF449342-AF1A-4D3F-B833-8F6DB8687F7D</gtr:id><gtr:name>Uppsala University Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/62C544E8-A6D5-4B0C-9773-7A30B21F968D"><gtr:id>62C544E8-A6D5-4B0C-9773-7A30B21F968D</gtr:id><gtr:name>University of Padua</gtr:name><gtr:address><gtr:line1>Universita di Padova</gtr:line1><gtr:line4>Padova</gtr:line4><gtr:postCode>35129</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/71B6CE06-9A78-427F-8FF2-50FCA9069AD8"><gtr:id>71B6CE06-9A78-427F-8FF2-50FCA9069AD8</gtr:id><gtr:name>Central Hospital of Bolzano</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F"><gtr:id>FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F</gtr:id><gtr:name>Baylor College of Medicine</gtr:name><gtr:address><gtr:line1>Baylor College of Medicine</gtr:line1><gtr:line2>Texas Medical Center</gtr:line2><gtr:line4>Houston</gtr:line4><gtr:line5>Texas</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/007E0817-B05C-490A-B38A-2EDA79558DDD"><gtr:id>007E0817-B05C-490A-B38A-2EDA79558DDD</gtr:id><gtr:name>Boston University</gtr:name><gtr:address><gtr:line1>One Sherborn Street</gtr:line1><gtr:line2>Boston</gtr:line2><gtr:line3>Massachusetts</gtr:line3><gtr:line4>MA 02215</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B62A7F23-290D-4D84-B017-FBBDF6E49E3D"><gtr:id>B62A7F23-290D-4D84-B017-FBBDF6E49E3D</gtr:id><gtr:name>University of Vermont</gtr:name><gtr:address><gtr:line1>University of Vermont</gtr:line1><gtr:line4>Burlington</gtr:line4><gtr:line5>Vermont</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8D42AFBE-6916-4BC6-8D6B-7BA1516690D2"><gtr:id>8D42AFBE-6916-4BC6-8D6B-7BA1516690D2</gtr:id><gtr:name>Malmo University Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/92B1EEF6-3D49-49C5-A7A5-5290AD810F6B"><gtr:id>92B1EEF6-3D49-49C5-A7A5-5290AD810F6B</gtr:id><gtr:name>University Medical Center Freiburg</gtr:name><gtr:address><gtr:line1>Robert-Koch-Str. 1</gtr:line1><gtr:postCode>D-79106</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C754D612-4D8B-42CB-922C-07E7F5BE4B49"><gtr:id>C754D612-4D8B-42CB-922C-07E7F5BE4B49</gtr:id><gtr:name>Washington University in St. Louis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0DE3D2C5-5503-42B3-A8A5-7F3FD1EE8DE8"><gtr:id>0DE3D2C5-5503-42B3-A8A5-7F3FD1EE8DE8</gtr:id><gtr:name>Geisinger Medical Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B"><gtr:id>22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B</gtr:id><gtr:name>University of Ulm</gtr:name><gtr:address><gtr:line1>Albert Einstein Allee 5</gtr:line1><gtr:line4>Ulm</gtr:line4><gtr:postCode>89081</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E68BE577-6C17-48CE-B65C-24C477BB8AE9"><gtr:id>E68BE577-6C17-48CE-B65C-24C477BB8AE9</gtr:id><gtr:name>Yeshiva University</gtr:name><gtr:address><gtr:line1>500 West 185th Street</gtr:line1><gtr:postCode>10033</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB"><gtr:id>60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB</gtr:id><gtr:name>Brigham and Women's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AD1B5C1D-39E1-4A1F-A58F-D5F2DE64FE7F"><gtr:id>AD1B5C1D-39E1-4A1F-A58F-D5F2DE64FE7F</gtr:id><gtr:name>Innsbruck Medical University</gtr:name><gtr:address><gtr:line1>Christoph-Probst-Platz 1</gtr:line1><gtr:line2>Innrain 52</gtr:line2><gtr:postCode>A-6020</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8A621CD6-4DE9-4B35-992C-631871D7793E"><gtr:id>8A621CD6-4DE9-4B35-992C-631871D7793E</gtr:id><gtr:name>University of Rochester</gtr:name><gtr:address><gtr:line1>PO Box 270001</gtr:line1><gtr:line4>Rochester</gtr:line4><gtr:line5>New York</gtr:line5><gtr:postCode>NY 14627</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8C250FB6-4890-4BF9-9C23-69E6B2E02B95"><gtr:id>8C250FB6-4890-4BF9-9C23-69E6B2E02B95</gtr:id><gtr:name>Wake Forest University</gtr:name><gtr:address><gtr:line1>Wake Forest University</gtr:line1><gtr:line2>1834 Wakeforest Road</gtr:line2><gtr:line4>Winston Salem</gtr:line4><gtr:line5>North Carolina</gtr:line5><gtr:postCode>NC 27106</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/926FCE3B-DFAB-4FE7-9BF8-7372B5AA9514"><gtr:id>926FCE3B-DFAB-4FE7-9BF8-7372B5AA9514</gtr:id><gtr:name>German Cancer Research Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AFCF678A-5FC2-4D86-B376-12C1457C0F14"><gtr:id>AFCF678A-5FC2-4D86-B376-12C1457C0F14</gtr:id><gtr:name>Columbia University Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC"><gtr:id>AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC</gtr:id><gtr:name>Johannes Gutenberg University of Mainz</gtr:name><gtr:address><gtr:line1>University of Mainz</gtr:line1><gtr:line4>Mainz</gtr:line4><gtr:postCode>D-55099</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4B98F259-77FE-4FC0-9296-140C9C066977"><gtr:id>4B98F259-77FE-4FC0-9296-140C9C066977</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Danesh</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A82DCE4F-9E98-4ADC-8584-4A6B0553268F"><gtr:id>A82DCE4F-9E98-4ADC-8584-4A6B0553268F</gtr:id><gtr:firstName>Chris</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Packard</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D4875E5B-C2B2-4BB4-BA70-E1170A00D2A7"><gtr:id>D4875E5B-C2B2-4BB4-BA70-E1170A00D2A7</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Thompson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C3A08924-3211-47F9-A709-DC28DAD85A96"><gtr:id>C3A08924-3211-47F9-A709-DC28DAD85A96</gtr:id><gtr:firstName>Rory</gtr:firstName><gtr:surname>Collins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601284"><gtr:id>E19540C9-C637-4604-BDBB-32EF18A1E92A</gtr:id><gtr:title>Reliable evaluation of associations between Lp-PLA2 markers and the risk of cardiovascular outcomes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601284</gtr:grantReference><gtr:abstractText>Heart attacks remain leading causes of death and disability in the UK and worldwide. Controlling known causes of heart disease (such as smoking, high blood pressure and raised cholesterol levels) substantially cuts the risk of disease. This success has encouraged the search for new causes which might further reduce risk, particularly if, like blood cholesterol levels, measuring or changing them can lead to improvements in disease prediction or prevention.

A blood enzyme known as Lp-PLA2 (?lipoprotein-associated phospholipase A2?) may play a direct role in narrowing the heart?s arteries and triggering heart attacks. Several studies have recently reported positive correlations between the amount (or activity) of Lp-PLA2 in the bloodstream and subsequent risk of heart disease. New medicines which almost completely block the activity of Lp-PLA2 (both in circulating blood and in arteries) have recently been invented and are being tested in early trials. 

In 2004 the US Food and Drug Administration approved for use a test (known as ?PLAC?) which measures blood levels of Lp-PLA2. But this test has not been widely adopted because it is not yet reliably known whether (or to what extent) Lp-PLA2 measurements can lead to useful improvements in the early detection of heart attacks. It is also not clear to what extent blood levels of Lp-PLA2 are correlated with the future occurrence of heart attacks in different situations, such as in initially healthy adults compared with patients who have a history of heart disease or stroke. Such information is important in planning large trials of Lp-PLA2-inhibiting medicines.

To help provide answers to these and other key questions, we will pool original data from at least 27 long-term medical surveys which have already recorded initial Lp-PLA2 levels in a total of about 75,000 individuals, of whom about 15,000 have developed heart disease or strokes since monitoring. This unique database will encompass almost the entirety of the world?s available epidemiological knowledge on Lp-PLA2 levels and cardiovascular diseases. Analyses of it will rapidly yield precise, comprehensive and reliable findings that will help to determine: (i) whether or not Lp-PLA2 measurement merits incorporation into routine screening tests for heart disease and (ii) the best way to test new Lp-PLA2-inhibiting medicines in large trials (eg, how many people are likely to be required? with what initial characteristics?).</gtr:abstractText><gtr:technicalSummary>Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that circulates largely bound to low-density lipoprotein (LDL) and lies directly on the pathogenic sequence from localised inflammation to atherosclerotic lesion formation. The potential applications of Lp-PLA2 markers in the prediction and prevention of cardiovascular diseases have already been recognized by development of a US FDA-approved assay for its measurement, and by discovery (and development) of potent Lp-PLA2 inhibitors that lower enzyme activity in plasma and at vascular sites. But, despite publication of a number of studies generally reporting positive associations between Lp-PLA2 markers and cardiovascular outcomes, more detailed epidemiological evidence is needed in order to help determine reliably the relevance of Lp-PLA2 markers to coronary heart disease (CHD) and other vascular outcomes.

We will pool individual participant (ie, primary) data on Lp-PLA2 markers from at least 27 prospective studies, involving about 15,000 incident cardiovascular outcomes and about 60,000 non-cases in a prospectively designed, systematic meta-analysis. The combined database will also comprise at least 5000 individuals with serial Lp-PLA2 measurements and at least 40,000 individuals with measurements of both Lp-PLA2 mass and activity. The main analyses will involve regression models stratified by study and sex; studies provided as prospective cohort studies will be analysed using Cox?s proportional hazards model. Potential sources of diversity in associations between Lp-PLA2 markers and CHD risk will be explored. 

Data emerging from this study will reliably: (i) quantify associations between Lp-PLA2 markers and CHD (and other vascular) outcomes under different circumstances (including characterisation of any dose-response relationships); (ii) determine the incremental predictive ability for CHD of these markers; (iii) clarify their distribution and values in various subgroups of the population; (iv) elucidate the degree of Lp-PLA2 biovariability in different situations; and (v) determine how well different Lp-PLA2 markers correlate with one another. These data should have potentially important and immediate clinical applications. There is a need to evaluate the utility of the FDA-approved Lp-PLA2 mass test (ie, the PLAC test produced by diaDexus, Inc) for CHD screening, which has been widely used in the studies contributing to the present collaboration. In addition, Lp-PLA2 is already a therapeutic target for several novel agents, including SB-480848 (a compound which has demonstrated the ability to reduce Lp-PLA2 activity in phase I and II trials), suggesting that these data may help to inform and optimize the design of planned phase III trials of such agents.</gtr:technicalSummary><gtr:fund><gtr:end>2009-08-19</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-08-20</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>311155</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Rochester</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>3C99D38E-BBED-49DC-AD0F-DF11915EC469</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-27</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johannes Gutenberg University of Mainz</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>39E2A1DA-5225-44AD-B0CE-645B8FFD702F</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-14</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brigham and Women's Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>1535E493-B6F3-4CE6-A57B-037A0AB3C1CB</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-5</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>DD37A806-B0FF-4E87-ADCA-AF49D5E3773E</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-22</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Washington</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>95D4D6A1-EA8A-4C24-A313-A3F8692EB3F5</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-30</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>3307FBBD-3C9E-4D6B-B6F3-63D7F2A5A012</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-23</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Helmholtz Association of German Research Centres</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Helmholtz Zentrum Munchen</gtr:department><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>7A5A58DC-4D33-4B0C-A354-A0CC9972B3E0</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-11</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Medical Center Freiburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>D20BFB4D-FAB9-499E-8E9B-3CD1C69C8D0A</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-8</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Innsbruck Medical University</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>A4114012-E620-4A3B-ABF6-AC4FCC47721D</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-18</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wake Forest University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Wake Forest School of Medicine</gtr:department><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>06F605F4-ECA8-42AC-B5A3-09512CDE34D1</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-33</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Texas Southwestern Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>0AAEB5B4-74EE-44A5-9846-A94E3C3DB6F0</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-28</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Boston University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>595A9ADB-9090-427F-87C2-E2036DE90E7C</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-4</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>5985C429-A687-4854-991E-4A98BA5AA273</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-12</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiology Frankfurt-Sachsenhausen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>10117FC9-2F09-4480-8ACA-CAEE94A5CCDF</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-6</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Malmo University Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>F8820BB0-B8A1-43A1-BAFA-E52A4FACEE02</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-16</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lund University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>AA63625D-F530-4BB4-8780-3088389292F6</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-15</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mayo Clinic</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>9946C016-435A-4E90-9CFE-7498117D103D</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-17</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Albert Einstein College of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>6B94B92A-4D26-475E-BC44-BE6EAD81E2F3</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-1</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Vermont</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>477426ED-066E-4721-AC56-F2925BFED782</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-31</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Erasmus University Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>56231FCB-5A81-421B-83B6-626019C2AB3B</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-7</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>59FE0AFC-5FAA-431A-B5E0-7959E5F4593B</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-25</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>German Cancer Research Center</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>7FDB6928-F3CA-48B4-AEB9-93775620F083</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-10</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Padova</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>E02981C1-F042-4FBD-A4F9-45B26A4C4489</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-26</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>7E0F4611-C602-4335-8B44-1A388EFED2E7</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-34</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ulm</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>EA590292-F514-4127-BCF0-5538BEF9AF70</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-29</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Intermountain Medical Centre</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>CC06E432-E0B7-495B-A39C-9605CE1EF956</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-13</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Geisinger Medical Centre</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>FE172EAF-5678-4B9C-A753-E418436FE98E</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-9</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Central Hospital of Bolzano</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>5B3C7CA1-717D-461B-B75C-F596708170AF</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-3</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>2C4592FC-2482-4CC1-921A-68D3D3A1FAE0</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-24</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Columbia University Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Neurological Institute of New York</gtr:department><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>97C01330-030F-4C74-B039-248730942F6C</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-20</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Texas Southwestern Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>45FDF880-0F66-4CFB-B999-65D657DF54C8</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-21</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Uppsala University Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>8E344656-70FC-453B-9638-E6BCE0A67878</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-32</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Baylor College of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>321DFA00-3A93-4509-B4B3-CD634FD9D12C</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-2</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Biostatistics Unit</gtr:department><gtr:description>Lp-PLA2 Studies Collaboration</gtr:description><gtr:id>8BB9E7F5-D78E-4189-BE91-F09E14359B80</gtr:id><gtr:impact>The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a &amp;pound;250m programme of trials of Lp-PLA2 inhibitors.</gtr:impact><gtr:outcomeId>672880E8BB1-19</gtr:outcomeId><gtr:partnerContribution>Investigators from 32 prospective studies shared primary data on 79,000 participants</gtr:partnerContribution><gtr:piContribution>i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Lp-PLA2 studies collaboration website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4C3D28EC-FB61-4037-8728-2B12E7A8C3DD</gtr:id><gtr:impact>A publicly accessible website was built. http://www.phpc.cam.ac.uk/MEU/LSC/

none</gtr:impact><gtr:outcomeId>AE31C2C37E2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media interviews</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C640CE3E-3413-4C9B-A198-F71DDDA9AEFD</gtr:id><gtr:impact>Interviews with representatives of the media to discuss potential implications of findings from the most comprehensive scientific study to date investigating Lp-PLA2 and cardiovascular risk.

Profiling of research by the BBC, Heart.org, and several national newspapers.</gtr:impact><gtr:outcomeId>EHEn1L1hqaj</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation of published protocol manuscript</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>8A3800DF-074B-4182-B00B-111954AA0D4D</gtr:id><gtr:impact>We have influenced international cardiovascular guidelines through evaluation of the incremental value of assessing established and emerging risk factors for risk assessment, including inflammation biomarkers (NEJM 2012), lipids and lipoproteins (JAMA 2012, Lancet 2010), adiposity measures (Lancet 2011), and carotid ultrasound (Lancet 2012).</gtr:impact><gtr:outcomeId>Qo8qdYpvdqS</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>LpPLA2 Studies Collaboration</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>ED54B7E5-56C9-4A67-9888-13506A75E8FB</gtr:id><gtr:outcomeId>cHwrLc1dzFq</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation of published protocol manuscript</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>2AD05E52-9FC1-4919-AF75-AA8BF07F6E8B</gtr:id><gtr:outcomeId>F905B22A2F6</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A database has been created of harmonised individual participant data records from over 110,000 individuals</gtr:description><gtr:id>EF65B8A3-4D46-4DD3-8B42-02742275B237</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>N8LyP75pLMv</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>The Lp-PLA2 Studies Collaboration database</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E1AC63C3-58F9-4599-B887-2B384D0844E0</gtr:id><gtr:title>Genetic invalidation of Lp-PLAas a therapeutic target: Large-scale study of five functional Lp-PLA-lowering alleles.</gtr:title><gtr:parentPublicationTitle>European journal of preventive cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06552a4b792277499d1f97dd583ddfee"><gtr:id>06552a4b792277499d1f97dd583ddfee</gtr:id><gtr:otherNames>Gregson JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2047-4873</gtr:issn><gtr:outcomeId>58c14cfb275ff4.14899954</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1682689F-A4AA-4D28-B66E-F5029FEAB4B7</gtr:id><gtr:title>Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c28a8e3c01a5869f6ea0a4fb7405366d"><gtr:id>c28a8e3c01a5869f6ea0a4fb7405366d</gtr:id><gtr:otherNames>Lp-PLA(2) Studies Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>56e0343c5fa221.12340428</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E69C3E5-F741-4ADD-80D3-FCB6565005DA</gtr:id><gtr:title>Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases.</gtr:title><gtr:parentPublicationTitle>European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology &amp; Prevention and Cardiac Rehabilitation and Exercise Physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e2a6b3c6a4b0c707fd643944594fab1"><gtr:id>6e2a6b3c6a4b0c707fd643944594fab1</gtr:id><gtr:otherNames>Lp-PLA2 Studies Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1741-8267</gtr:issn><gtr:outcomeId>56e13466be2141.67279953</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FC82E83-51CA-4523-B6E0-02926A1C1AE1</gtr:id><gtr:title>Lipid-related markers and cardiovascular disease prediction.</gtr:title><gtr:parentPublicationTitle>JAMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00954130f581451305ebfe461866731f"><gtr:id>00954130f581451305ebfe461866731f</gtr:id><gtr:otherNames>Emerging Risk Factors Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0098-7484</gtr:issn><gtr:outcomeId>56e033d5165947.26715493</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D83BD194-FC29-4059-ACA0-D182AA205CC6</gtr:id><gtr:title>Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA(2) and cardiovascular diseases</gtr:title><gtr:parentPublicationTitle>EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION &amp; REHABILITATION</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/197c32830ea221adf7b91637117cd55b"><gtr:id>197c32830ea221adf7b91637117cd55b</gtr:id><gtr:otherNames>Ballantyne C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1741-8267</gtr:issn><gtr:outcomeId>5a36011827a596.89104918</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601284</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>